Digital brain biomarker company Monument Therapeutics raises £2.6 million Digital brain biomarker company Monument Therapeutics raises £2.6 million By matt.poulter|2021-08-13T14:02:02+00:00July 1st, 2021| Read More
Latent inhibition and its potential as a biomarker for schizophrenia By matt.poulter|2021-05-21T11:57:22+00:00May 21st, 2021| Read More
Richard Bungay Joins the Board as a Director Richard Bungay Joins the Board as a Director By matt.poulter|2021-05-21T12:11:24+00:00June 29th, 2017| Read More
Postoperative cognitive dysfunction: an acute approach for the development of novel treatments for neuroinflammation By matt.poulter|2021-05-25T20:00:41+00:00November 2nd, 2016| Read More
